|
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia |
Jul 2023 |
Annals of Hematology |
Aplastic Anemia |
|
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
Apr 2019 |
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
|
Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
May 2019 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
Sep 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
Sep 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
Jun 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
Jan 2020 |
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
